Fleischmann, Roy http://orcid.org/0000-0002-6630-1477
Blanco, Ricardo
Van den Bosch, Filip http://orcid.org/0000-0002-3561-5932
Bessette, Louis
Song, Yanna
Penn, Sara K.
McDearmon-Blondell, Erin
Khan, Nasser
Chan, Kelly
Mysler, Eduardo
Clinical trials referenced in this document:
Documents that mention this clinical trial
FRI0089 COMPARATIVE EFFICACY (ACR 20) OF TOCILIZUMAB TO OTHER TARGETED IMMUNE MODULATORS (TIM) FOR RHEUMATOID ARTHRITIS: A NETWORK META-ANALYSIS (NMA)
https://doi.org/10.1136/annrheumdis-2020-eular.532
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
https://doi.org/10.1136/annrheumdis-2019-215764
OP0225 EVALUATION OF RESPONSE TO ADJUVANTED RECOMBINANT ZOSTER VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB: RESULTS FROM A RANDOMIZED TRIAL SUB-STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.2386
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2020-218412
FRI0137 UPADACITINIB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM SELECT-COMPARE
https://doi.org/10.1136/annrheumdis-2019-eular.287
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2023-223916
Waiting for JAK inhibitor safety data
https://doi.org/10.1136/rmdopen-2022-002236
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
https://doi.org/10.1007/s40744-024-00658-1
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (Post-results)
https://doi.org/10.1136/annrheumdis-2020-218510
Funding for this research was provided by:
AbbVie
Article History
Received: 15 December 2023
Accepted: 21 February 2024
First Online: 18 March 2024
Declarations
:
: Roy Fleischmann has received consulting fees and/or grant/research support from AbbVie, Amgen, BI, Biosplice, BMS, DREN Bio, Flexion, Galapagos, Galvani, Genentech, Gilead, GSK, Horizon, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, Selecta, Teva, UCB, Viela, Vorso, and Vyne. Ricardo Blanco has received grant/research support from AbbVie, MSD, and Roche; and consulting fees/participated in speaker’s bureau from AbbVie, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, and Roche. Filip Van den Bosch has received speaker and/or consulting fees from AbbVie, Amgen, BMS, Galapagos, Janssen, Lilly, Merck, Novartis, Sanofi, and UCB. Louis Bessette has received speaking fees, consulting fees, and grant/research support from AbbVie, Amgen, BMS, Celgene, Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Organon, Pfizer, Roche, Sanofi-Aventis, Teva, and UCB. Yanna Song, Sara K. Penn, Erin McDearmon-Blondell, Nasser Khan, and Kelly Chan are employees of AbbVie and may hold stock or options. Eduardo Mysler has received speaking fees, consulting fees, and grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Hi-Bio, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, and Sanofi.
: This study is being conducted according to the International Council for Harmonization guidelines, local regulations and guidelines governing clinical study conduct, and the Declaration of Helsinki. All patients provided written informed consent, and the study protocol and consent forms were approved by an institutional review board or independent ethics committee at each study site. Approval was received from the master ethics committee, the Advarra Institutional Review Board (Pro00034396).